Pfizer Inc. will begin enrolling boys with Duchenne muscular dystrophy in a Phase III clinical trial in the second half of 2020, despite serious cases of complement activation in boys treated with the experimental gene therapy in Phase Ib.
Pfizer will initiate a Phase III clinical trial testing its gene therapy PF-06939926 in the second half of 2020 with...